Sign in
Taking people in United StatesPhase 2

Tests cabozantinib to prevent cancer return in children with high-risk solid tumors

Tests cabozantinib as maintenance treatment in young people with neuroblastoma or sarcoma.

Key facts

Who runs it
Nationwide Children's Hospital
Where
Aurora, Birmingham, Columbus, Salt Lake City, The Bronx, and Washington D.C., United StatesSee the 6 sites
Trial code
Registry title
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Status
Recruiting
Phase
Phase 2
People taking part
86 people, planned
Started
20 Jul 2022
Expected to end
Dec 2029
Type of study
Interventional
Treatments tested
  • Cabozantinib
Record updated
12 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults with high-risk solid tumors, such as neuroblastoma or sarcoma, who finished their latest treatment and have little or no disease left.

Age
From 18 months to under 40 years.
Sex
All sexes can join.
Disease stage
High-risk solid tumors with a 1-year chance of no progression of 25% or less, such as neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, or Wilms tumor. Most must be at first relapse or later; some metastatic cancers after first treatment can also join. Disease must be measurable or evaluable at the start of the latest treatment.
Earlier treatment
Must have finished their most recent line of treatment and be able to start the study drug within 12 weeks of its end. Waiting periods apply after chemotherapy, targeted drugs, antibody or cell therapy, radiation, and high-dose therapy with stem cell rescue.
Biomarker or test result
Not asked, except that some rhabdomyosarcoma groups are described as alveolar or fusion-positive.

Main reasons for not taking part

  • Major surgery, laparoscopic surgery, or trauma needing hospital stay within 4 weeks
  • Lung procedure or collapsed lung within 4 weeks
  • Central line or port placed, changed, or removed within 7 days
  • Heart rhythm problems, stroke, mini-stroke, or heart attack within 6 months
  • Cannot swallow tablets whole

The registry criteria, word for word

Show all 27 criteriaShow less

Other criteria

  • 3.2 Patient Eligibility Criteria:
  • 3.2.1 Assessment criteria for eligibility, based on disease burden at start of most recent line of therapy and corresponding response (patients must meet one of the following criteria in order to be deemed eligible for enrollment):
  • Patients previously with measurable disease, at start of most recent line of therapy, AND without evaluable disease (or for whom assessment of potential evaluable-only disease would not be considered standard of care) are eligible based on "measurable disease response" only in Section 3.1.2.a.i
  • Patients previously with evaluable disease at start of most recent line of therapy, AND without measurable disease at that time are eligible based on "evaluable disease" definition alone only in Section 3.1.2.a.ii
  • Patients previously with measurable AND evaluable disease at start of most recent line of therapy must meet BOTH "measurable disease" and "evaluable disease" definitions under Section 3.1.2.a; 3.2.2. Disease Strata. Patients need to meet any single definition of disease below:
  • Stratum A: Solid tumors with 1-year PFS ≤25% (target enrollment 36 patients); Neuroblastoma BR1 at the end of frontline therapy with residual disease (less than complete response (CR), including MIBG-avid stable disease as per Section 3.1.2.a.ii,.or >5% bone marrow involvement) but not progressive at time of enrollment; Neuroblastoma BR2 or later; Osteosarcoma, BR2 or later; Ewing sarcoma, BR2 or later; Rhabdomyosarcoma, with positive surgical margins OR with primary extremity tumor with >2 metastases at diagnosis, BR1 or later; Rhabdomyosarcoma, alveolar subtype or fusion-positive subtype, BR2 or later; Rhabdomyosarcoma, embryonal subtype, Group 4 at original diagnosis, BR2 or later; Desmoplastic small round blue cell tumor, BR2 or later; Any other soft tissue sarcoma, BR2 or later; Wilms tumor, diffuse anaplasia histology, any stage, BR2 or later; Wilms tumor, any histology with relapse within 12 months of diagnosis, who have received prior treatment with doxorubicin, and intraabdominal recurrence, BR2 or later; Wilms tumor, BR3 or later; Other solid tumor with 1-year PFS ≤ 20% can be discussed with study chair for eligibility
  • Stratum B: Metastatic Ewing sarcoma with metastases not undergoing complete metastatectomy, BR1 (target enrollment 20 patients)
  • Stratum C: Metastatic osteosarcoma after frontline therapy, BR1 (target enrollment 20 patients)
  • Stratum D: Metastatic fusion-positive rhabdomyosarcoma after frontline therapy, BR1 (target enrollment 10 patients); 3.2.3 Inclusion Criteria for Eligibility:
  • Age: ≥ 18 months of age and <40 years of age at time of study enrollment
  • Performance level: Patients must have a Lansky or Karnofsky performance status score of ≥ 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are upright in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. Patients should also have recovery to baseline or ≤ Grade 1 CTCAE v4.03 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy (see Section 3.2.3, criteria 4)
  • Patient Body Surface Area (BSA): Patients must be ≥0.35 m2 in BSA, using the Mosteller formula, BSA = (((Height in cm) * (Weight in kg))/ 3600)½ within two weeks of study enrollment
  • Prior therapy: patients must have recovered from the acute toxic effects of prior therapy, with the following time specifications:; Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment on study (6 weeks if prior therapy included nitrosourea); Other medicinal anti-cancer agents: Patients must not have received non-myelosuppressive anticancer agents, including any type of small molecule kinase inhibitor, within 14 days of enrollment on study; Biological anticancer therapy (including antibody therapy or cellular therapy): Patients must not have received biological anticancer therapy within 21 days of enrollment on study; Radiation therapy: Patients must not have received external beam radiation therapy to sites outside of the lungs within 2 weeks of study enrollment, external beam radiation therapy to sites within the lungs within 4 weeks of study enrollment, or I-131 MIBG therapy within 6 weeks of study enrollment. Subjects with clinically relevant ongoing complications from prior radiation therapy MUST be discussed with Study Chair or his proxy to determine suitability and safety of enrollment; Myeloablative therapy: Patients must not have received myeloablative therapy within 2 months of study enrollment, must not have received a blood stem cell/marrow infusion within 3 weeks of study enrollment, and must have attained blood count recovery as per Section 3.2.3, criteria 5
  • Bone Marrow Function: Patients must have adequate bone marrow function at time of study enrollment, as defined as:; Absolute neutrophil count (ANC) ≥1000/mcL; patients cannot have received filgrastim, pegfilgrastim or equivalent biosimilar within 14 days of study enrollment; Platelet count ≥ 100,000/mcL; patients can receive no more than 15 mL/kg of platelet transfusions per week at time of enrollment to meet the parameters; patients can receive a TPO agonist (e.g., eltrombopag or romiplostim) at time of enrollment but must be on a stable dose for at least 14 days prior to enrollment; Hemoglobin ≥ 8.0 g/dL; patients can receive no more than 10 mL/kg of packed red blood cells (PRBCs)/week transfused at time of enrollment on therapy to meet the parameters; patients may receive erythropoietin or biosimilar equivalent but must have been on a stable dose and not require PRBC transfusions for at least 14 days prior to study enrollment; Patients with residual bone marrow metastases at end of most recent line of therapy must have stable disease or better at two bone marrow evaluations at least 4 weeks apart, with the second marrow assessment at least 4 weeks after end of most recent therapy. Stable disease is defined as <2-fold change in marrow burden between the two timepoints and ≤20% marrow involvement. When bilateral bone marrow assessment is performed, average marrow involvement of the two sites will be used for eligibility
  • Renal Function: Patient must meet criteria for both a. and b. below to have adequate renal function, within 2 weeks of study enrollment; Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, as per institutional standard testing OR serum creatinine based on age/gender as listed in protocol:; Urine protein: ≤ 30 mg/dl in urinalysis (clean catch recommended), equivalent to ≤ 1+ on dipstick OR quantitative urine protein < 1000 mg in a 24hr urine sample. NOTE: If the initial urinalysis shows >30 mg/dL urine protein (or > 1+ on dipstick), a 24-hour quantitative urine protein should be utilized, as described above, for eligibility consideration
  • Hepatic function: Patient must meet ALL of the below criteria, within 14 days of study enrollment, to have adequate hepatic function:; Total bilirubin < 2x institutional upper limit of normal (ULN) for age; ALT<5x ULN; Serum albumin >2.7 g/dL
  • Cardiovascular Function: Patients must have adequate cardiovascular function as defined as:; No significant arrhythmias, strokes, transient ischemic attacks, or myocardial infarction within 6 months of study enrollment; QTc ≤ 480 msec within 7 days of study enrollment (calculated using Bazett calculation or Fridericia calculation as per institutional standard of care; whichever calculation is used for eligibility must be used for all future QTc calculations); A single ECG with QTc meeting the above criterion is adequate. However, if an initial ECG shows a QTc >480 ms, obtain two additional ECGs with each ECG at least 30 minutes apart. Calculate each individual QTc by the same calculation method and average the values; the resulting average QTc will be used for eligibility; Blood pressure ≤ 95th percentile for age, height, and gender for patients <18 years of age (78), or BP ≤140/90 for patients ≥18 years of age. At time of enrollment, patients may be on one antihypertensive agent at a stable dose for at least 2 weeks prior to enrollment
  • Pancreatic function: Patient must have adequate pancreatic function, as defined by a serum lipase <2x ULN
  • Neurologic function: Patients with defined seizures who are on a stable anti- convulsant regimen using drugs that do not induce hepatic metabolizing enzymes for at least 4 weeks are eligible for enrollment Recommended Non-enzyme inducing anticonvulsants Clonazepam Diazepam Ethosuximide Ezogabine Gabapentin Lacosamide Lamotrigine Levetiracetam Lorazepam Perampanel Tiagabine Topiramate Valproic Acid Zonisamide Unacceptable Enzyme inducing anticonvulsants Carbamazepine Felbamate Phenobarbital Fosphenytoin Phenytoin Primidone Oxcarbazepine
  • Lung integrity: Patients must not have had any invasive pulmonary procedure (including bronchoalveolar lavage, lung biopsy, transbronchial biopsy, or thoracotomy) or pneumothorax within 4 weeks of enrollment on study
  • Surgeries or trauma:; Patients must not have had any major surgical procedures, laparoscopic procedures, sepsis, shock, or physical trauma requiring hospitalization within 4 weeks of enrollment on study. The primary surgeon of any major surgical procedures must authorize antineoplastic treatment before enrollment on study; Patients must not have had a central line or subcutaneous port placement, revision, or removal (excluding a peripherally inserted central catheter (PICC)) within 7 days of study enrollment. Advise patients with a surgically placed central line or subcutaneous port that removal of the port once enrolled on study would require holding study treatment for 4 weeks prior, and surgical removal of the central line or port would be recommended to be performed prior to cabozantinib initiation; Patients must not have had a core or fine needle biopsy within 7 days of study enrollment; Any surgical wounds or incisions must be healed, as determined by treating physician, prior to enrollment on study; Bone marrow aspiration and/or biopsy are not considered surgical procedures for the purpose of this study
  • Patients must be able to swallow tablets intact. Tablets cannot be cut or crushed
  • Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment. Post-menarchal females must be confirmed to not be pregnant at time of enrollment
  • Patient or legal guardian must be capable of understanding and complying with the protocol requirements and must have signed the informed consent document
  • Patient must be able to start study treatment no later than 12 weeks after end of prior therapy, where 1 week = 7 days
  • Patient must be enrolled on study within 14 days of qualifying radiographic imaging studies demonstrating best response as per Section 3.1.2
  • Patient must be able to start study treatment no later than 7 days from study enrollment; SEE PROTOCOL FOR ADDITIONAL EXCLUSION CRITERIA

Where in United States

  • Children's Hospital of ColoradoAurora, United StatesContact: Emily Blauel, MDTaking people
  • Children's Hospital of Alabama/UABBirmingham, United StatesContact: Elizabeth Alva, MD, MSPHTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Kelly HadingerTaking people
  • Primary Children's HospitalSalt Lake City, United StatesContact: Matthew Dietz, MDTaking people
  • Children's Hospital at MontefioreThe Bronx, United StatesContact: Alice Lee, MDTaking people
  • Children's National Medical CenterWashington D.C., United StatesContact: Kim AeRang, MDTaking people

About the trial

What the trial wants to find out

This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted.

Read full original descriptionShow less

The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure.

The group in the trial

  • CabozantinibTreatment being tested

    Enrolled patients will be treated with cabozantinib maleate, tablet formulation, using the recommended Phase 2 dose of 40 mg/m2/day, to a maximum of 420 mg/week. Treatment will be administered in 28- day cycles.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Plain-language title
Tests cabozantinib to prevent cancer return in children with high-risk solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 August 2025